Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
October 17, 2024
Lead Product(s) : Fecal Microbiota
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Topelia Therpeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Vancomycin and Fecal Microbiota Transplant in a Single Patient With Autism Spectrum Disorder
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
May 07, 2021
Lead Product(s) : Fecal Microbiota
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Topelia Therpeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fecal Microbiota
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Ventura Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Familial Fecal Microbiota Transplant for the Treatment of Subjects With Autism Spectrum Disorders
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : Fecal Microbiota
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Ventura Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial of Combination Therapy to Treat COVID-19 Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2020
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Big Corona
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Combination Therapies to Treat COVID-19 Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2020
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Big Corona
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxychloroquine Sulphate,Azithromycin,Ascorbic Acid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Progenabiome Begins Hydroxychloroquine Clinical Trials
Details : The clinical trial protocol will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2020
Lead Product(s) : Hydroxychloroquine Sulphate,Azithromycin,Ascorbic Acid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rescure
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Rinati Skin
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ResCureâ„¢ to Treat COVID-19 Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2020
Lead Product(s) : Rescure
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Rinati Skin
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : DSCS CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Quintuple Therapy to Treat COVID-19 Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2020
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : DSCS CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : DSCS CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2020
Lead Product(s) : Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : DSCS CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
August 14, 2019